1. Tarlatamab, a bispecific T-cell engager targeting delta-like ligand 3, significantly prolonged overall survival in small-cell lung cancer patients.
2. Patients receiving tarlatamab experienced improved progression-free survival and tumor response rates compared to standard chemotherapy.
3. Tarlatamab demonstrated reduced high-grade toxicities in the trial.
4. 71% of trial participants had received prior anti–PD-1 or anti–PD-L1 therapy.
5. Patient-reported outcomes showed greater reductions in dyspnea and cough with tarlatamab.
6. Grade ≥3 adverse events occurred in 54% of tarlatamab-treated patients vs. 80% with chemotherapy.
7. Additional trials are ongoing to explore earlier-line use of tarlatamab.

Source: NEJM